Motavizumab (MEDI-524)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Motavizumab (MEDI-524), covering 2013-08-28 to 2013-08-28. Get the full timeline:
Most recent: Clinical Trial Update: Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children [Phase 3]